Clinical Decision Thresholds for Surfactant Administration in Preterm Infants: a Systematic Review and Network Meta-analysis

Overview

Journal EClinicalMedicine

Specialty General Medicine

Date 2023 Aug 4

PMID 37538537

Authors

Viraraghavan Vadakkencherry Ramaswamy

Tapas Bandyopadhyay

Thangaraj Abiramalatha

Abdul Kareem Pullattayil S

Tomasz Szczapa

Clyde J Wright

Charles Christoph Roehr

Affiliations

Soon will be listed here.

Abstract

Background: The ideal threshold at which surfactant administration in preterm neonates with respiratory distress syndrome (RDS) is most beneficial is contentious. The aim of this systematic review was to determine the optimal clinical criteria to guide surfactant administration in preterm neonates with RDS.

Methods: The systematic review was registered in PROSPERO (CRD42022309433). Medline, Embase, CENTRAL and CINAHL were searched from inception till 16th May 2023. Only randomized controlled trials (RCTs) were included. A Bayesian random effects network meta-analysis (NMA) evaluating 33 interventions was performed. The primary outcome was requirement of invasive mechanical ventilation (IMV) within 7 days of life.

Findings: 58 RCTs were included. In preterm neonates ≤30 weeks after adjusting for the confounding factor of modality of surfactant administration, an arterial alveolar oxygen tension ratio (aAO) <0.36 (FiO: 37-55%) was ranked the best threshold for decreasing the risk of IMV, very low certainty. Further, surfactant administration at an FiO 40-45% possibly decreased mortality compared to rescue treatment when respiratory failure was diagnosed, certainty very low. The reasonable inference that could be drawn from these findings is that surfactant administration may be considered in preterm neonates of ≤30 weeks' with RDS requiring an FiO ≥ 40%. There was insufficient evidence for the comparison of FiO thresholds: 30% vs. 40%. The evidence was sparse for surfactant administration guided by lung ultrasound. For the sub-group >30 weeks, nebulized surfactant administration at an FiO < 30% possibly increased the risk of IMV compared to Intubate-Surfactant-Extubate at FiO < 30% and 40%, and less invasive surfactant administration at FiO 40%, certainty very low.

Interpretation: Surfactant administration may be considered in preterm neonates of ≤30 weeks' with RDS if the FiO requirement is ≥40%. Future trials are required comparing lower FiO thresholds of 30% vs. 40% and that guided by lung ultrasound.

Funding: None.

Citing Articles

Changes in practice of less-invasive surfactant administration (LISA) in United Kingdom neonatal units.

Shetty S, Tolentino D, Lau C, Duffy D, Greenough A Acta Paediatr. 2024; 114(2):393-397.

PMID: 39377490 PMC: 11706752. DOI: 10.1111/apa.17446.

Pulse oximetry in pediatric care: Balancing advantages and limitations.

Al-Beltagi M, Saeed N, Bediwy A, Elbeltagi R World J Clin Pediatr. 2024; 13(3):96950.

PMID: 39350904 PMC: 11438930. DOI: 10.5409/wjcp.v13.i3.96950.

Do Different Amounts of Exogenous Surfactant Differently Influence Cerebrovascular Instability in a Consecutive Group of Preterm Babies? Preliminary Results from a Single-Center Experience.

Calandrino A, Caruggi S, Vinci F, Battaglini M, Massirio P, Cipresso G Children (Basel). 2024; 11(9).

PMID: 39334621 PMC: 11429964. DOI: 10.3390/children11091088.

Non-Invasive Ventilatory Support in Preterm Neonates in the Delivery Room and the Neonatal Intensive Care Unit: A Short Narrative Review of What We Know in 2024.

Roehr C, Farley H, Mahmoud R, Ojha S Neonatology. 2024; 121(5):576-583.

PMID: 39173610 PMC: 11446298. DOI: 10.1159/000540601.

Using a simplified Downes score to predict the receipt of surfactant in a highly resourced setting.

Chotas W, Edwards E, Horn D, Soll R, Ehret D J Perinatol. 2024; 45(1):30-35.

PMID: 39103471 PMC: 11711085. DOI: 10.1038/s41372-024-02086-z.

References

Gaertner V, Thomann J, Bassler D, Ruegger C . Surfactant Nebulization to Prevent Intubation in Preterm Infants: A Systematic Review and Meta-analysis. Pediatrics. 2021; 148(5). DOI: 10.1542/peds.2021-052504. View

Merritt T, Hallman M, Berry C, Pohjavuori M, EDWARDS 3rd D, Jaaskelainen J . Randomized, placebo-controlled trial of human surfactant given at birth versus rescue administration in very low birth weight infants with lung immaturity. J Pediatr. 1991; 118(4 Pt 1):581-94. DOI: 10.1016/s0022-3476(05)83387-6. View

Sabzehei M, Basiri B, Shokouhi M, Ghahremani S, Moradi A . Comparison of minimally invasive surfactant therapy with intubation surfactant administration and extubation for treating preterm infants with respiratory distress syndrome: a randomized clinical trial. Clin Exp Pediatr. 2021; 65(4):188-193. PMC: 8990950. DOI: 10.3345/cep.2021.00297. View

Konishi M, Fujiwara T, Chida S, Maeta H, Shimada S, Kasai T . A prospective, randomized trial of early versus late administration of a single dose of surfactant-TA. Early Hum Dev. 1992; 29(1-3):275-82. DOI: 10.1016/0378-3782(92)90164-c. View

Ramaswamy V, Bandyopadhyay T, Abiramalatha T, S A, Szczapa T, Wright C . Clinical decision thresholds for surfactant administration in preterm infants: a systematic review and network meta-analysis. EClinicalMedicine. 2023; 62:102097. PMC: 10393620. DOI: 10.1016/j.eclinm.2023.102097. View

Rodriguez-Fanjul J, Jordan I, Balaguer M, Batista-Munoz A, Ramon M, Bobillo-Perez S . Early surfactant replacement guided by lung ultrasound in preterm newborns with RDS: the ULTRASURF randomised controlled trial. Eur J Pediatr. 2020; 179(12):1913-1920. PMC: 7378405. DOI: 10.1007/s00431-020-03744-y. View

Hentschel R, Dittrich F, Hilgendorff A, Wauer R, Westmeier M, Gortner L . Neurodevelopmental outcome and pulmonary morbidity two years after early versus late surfactant treatment: does it really differ?. Acta Paediatr. 2009; 98(4):654-9. DOI: 10.1111/j.1651-2227.2008.01216.x. View

Kribs A, Roll C, Gopel W, Wieg C, Groneck P, Laux R . Nonintubated Surfactant Application vs Conventional Therapy in Extremely Preterm Infants: A Randomized Clinical Trial. JAMA Pediatr. 2015; 169(8):723-30. DOI: 10.1001/jamapediatrics.2015.0504. View

Isayama T, Chai-Adisaksopha C, McDonald S . Noninvasive Ventilation With vs Without Early Surfactant to Prevent Chronic Lung Disease in Preterm Infants: A Systematic Review and Meta-analysis. JAMA Pediatr. 2015; 169(8):731-9. DOI: 10.1001/jamapediatrics.2015.0510. View

10.

Dargaville P, Kamlin C, Orsini F, Wang X, De Paoli A, Kanmaz Kutman H . Effect of Minimally Invasive Surfactant Therapy vs Sham Treatment on Death or Bronchopulmonary Dysplasia in Preterm Infants With Respiratory Distress Syndrome: The OPTIMIST-A Randomized Clinical Trial. JAMA. 2021; 326(24):2478-2487. PMC: 8715350. DOI: 10.1001/jama.2021.21892. View

11.

Gortner L, Wauer R, Hammer H, Stock G, Heitmann F, Reiter H . Early versus late surfactant treatment in preterm infants of 27 to 32 weeks' gestational age: a multicenter controlled clinical trial. Pediatrics. 1998; 102(5):1153-60. DOI: 10.1542/peds.102.5.1153. View

12.

Vaucher Y, Harker L, Merritt T, Hallman M, Gist K, Bejar R . Outcome at twelve months of adjusted age in very low birth weight infants with lung immaturity: a randomized, placebo-controlled trial of human surfactant. J Pediatr. 1993; 122(1):126-32. DOI: 10.1016/s0022-3476(05)83505-x. View

13.

Kandraju H, Murki S, Subramanian S, Gaddam P, Deorari A, Kumar P . Early routine versus late selective surfactant in preterm neonates with respiratory distress syndrome on nasal continuous positive airway pressure: a randomized controlled trial. Neonatology. 2012; 103(2):148-54. DOI: 10.1159/000345198. View

14.

Ainsworth S . Pathophysiology of neonatal respiratory distress syndrome: implications for early treatment strategies. Treat Respir Med. 2005; 4(6):423-37. DOI: 10.2165/00151829-200504060-00006. View

15.

Egberts J, de Winter J, Sedin G, De Kleine M, Broberger U, van Bel F . Comparison of prophylaxis and rescue treatment with Curosurf in neonates less than 30 weeks' gestation: a randomized trial. Pediatrics. 1993; 92(6):768-74. View

16.

Papile L, BURSTEIN J, Burstein R, KOFFLER H . Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr. 1978; 92(4):529-34. DOI: 10.1016/s0022-3476(78)80282-0. View

17.

Herting E, Kribs A, Hartel C, Von der Wense A, Weller U, Hoehn T . Two-year outcome data suggest that less invasive surfactant administration (LISA) is safe. Results from the follow-up of the randomized controlled AMV (avoid mechanical ventilation) study. Eur J Pediatr. 2020; 179(8):1309-1313. PMC: 7351829. DOI: 10.1007/s00431-020-03572-0. View

18.

Nayeri F, Esmaeilnia Shirvani T, Aminnezhad M, Amini E, Dalili H, Bijani F . Comparison of INSURE method with conventional mechanical ventilation after surfactant administration in preterm infants with respiratory distress syndrome: therapeutic challenge. Acta Med Iran. 2014; 52(8):596-600. View

19.

Abiramalatha T, Ramaswamy V, Bandyopadhyay T, Somanath S, Shaik N, Pullattayil A . Interventions to Prevent Bronchopulmonary Dysplasia in Preterm Neonates: An Umbrella Review of Systematic Reviews and Meta-analyses. JAMA Pediatr. 2022; 176(5):502-516. DOI: 10.1001/jamapediatrics.2021.6619. View

20.

Ng E, Shah V . Guidelines for surfactant replacement therapy in neonates. Paediatr Child Health. 2021; 26(1):35-49. PMC: 7850281. DOI: 10.1093/pch/pxaa116. View